About Bexsero

WHAT YOU NEED TO KNOW ABOUT BEXSERO

It’s the first and only meningitis B vaccine that can be used for the age groups that between 2012 to 2019 had the highest disease incidence, infants aged 1 year and younger. BEXSERO is indicated for individuals 2 months through 25 years of age, to help protect against disease caused by Neisseria meningitidis group B strains (meningitis B).

BEXSERO helps provide protection against meningitis B*, which can cause serious, and sometimes life-threatening infections such as:

Meningitis (infection of the lining of the brain and spinal cord)†
Sepsis (blood poisoning)†

These infections require immediate medical attention.

DID YOU KNOW?

49.5^%

of invasive meningococcal disease (IMD) cases in Canada were caused by meningitis B from 2012 through 2019.^‡

73^%

of IMD cases in infants and young children (aged ≤4 years) were caused by serogroup B.

Vaccination against meningitis B* is not part of your child’s routine vaccination schedule.

Help protect your child against meningococcal disease caused by meningitis B.*

* Meningococcal disease caused by Neisseria meningitidis group B strains.

† BEXSERO does not treat or reduce the consequences of meningococcal disease, including meningitis, sepsis, and death.

‡ Based on most recent data available.

Dosing

Recommended vaccination schedule, based on your child’s age:

For infants aged 2 months to 5 months, there are two possible dosing schedules. If you aren’t sure how many doses your child should receive, please check with their doctor.

Infant aged 2 months through 5 months of age (2 doses +1 booster)

PRIMARY IMMUNIZATION

2 primary doses*† - Each dose is 0.5 mL

At least 2 months apart

1 booster dose – (0.5 mL)

Required in the 2nd year of life after an interval of ≥6 months from the last injection of the initial course.

Infant aged 6 months through 11 months of age

PRIMARY IMMUNIZATION

2 primary doses – Each dose is 0.5 mL

At least 2 months apart

1 booster dose – (0.5 mL)

Required in the 2nd year of life after an interval of ≥2 months from the last dose.

Child aged 12 months through 23 months of age

PRIMARY IMMUNIZATION

2 primary doses – Each dose is 0.5 mL

At least 2 months apart

1 booster dose – (0.5 mL)

Required after an interval of 12 to 23 months from the last dose.

Child, adolescent or adult aged 2 years through 25 years of age

PRIMARY IMMUNIZATION

2 primary doses – Each dose is 0.5 mL

At least 1 month apart

1 booster dose – (0.5 mL)

May be considered in individuals at continuous risk of exposure to meningococcal disease.

* The initial course can also be given as 3 injections with ≥1 month interval between the primary doses. A booster dose should be given in the 2nd year of life after an interval of ≥6 months from the last injection of the initial course.

† The need for, and timing of further doses has not yet been determined.

To download this dosing schedule, click on the button below.

Download This Schedule

Make sure that your child gets all prescribed doses. This allows your child to get the full benefits of BEXSERO.

Potential side effects

Like all vaccines, BEXSERO may cause side effects, although not everybody gets them.

When BEXSERO is administered, the very common side effects* (affecting more than 1 in 10 people) your child may experience at the site of injection include:

pain/tenderness
redness of the skin
swelling of the skin
hardness of the skin

* Reported in all age groups 2 months through 25 years of age.

Side effects may occur after receiving this vaccine. Click to view possible side effects by age group:

Infants and children (2 months to 10 years of age)

Individuals 11 years of age or older

Reporting a side effect (or adverse event)

If you need to report an adverse event, please call 1-800-387-7374.

Please note: Your healthcare professional is the best source of information regarding your health. You are advised to discuss the advantages and disadvantages of BEXSERO with your healthcare professional before receiving the vaccine.

For complete instructions, see the Consumer Information leaflet that comes with your BEXSERO prescription.

BEXSERO multicomponent meningococcal B vaccine (recombinant, adsorbed) is a vaccine for the prevention of invasive meningococcal group B disease caused by Neisseria meningitidis group B bacteria (germs). These germs can cause invasive meningococcal group B disease (also known as Meningitis B) which can lead to serious, and sometimes life-threatening, infections such as meningitis (infection of the lining of the brain and spinal cord) and sepsis (blood poisoning). BEXSERO is given to individuals from 2 months through 25 years of age. As with any vaccine, BEXSERO may not fully protect all of those who are vaccinated. BEXSERO does not treat or reduce the consequences of meningococcal meningitis, including meningitis, sepsis, and death. Ask your healthcare professional if BEXSERO is right for your child. Full product information can be found at http://gsk.ca/bexsero/en. To report an adverse event, please call 1-800-387-7374.

For information about how GSK uses, shares, and protects personal information, including information collected online, please read GSK's Privacy Statement.

Please note: This site does not provide medical advice. The contents of this site are for information purposes only and are not in any way intended to replace or substitute the advice of your healthcare professional. Your healthcare professional is the best source of information regarding your health. This digital channel is not intended as a means for reporting an adverse event (side effect) or complaint for any GlaxoSmithKline product. To report an adverse event or product complaint, please call 1-800-387-7374. This site is intended for use by Canadian residents only.

04854
02/23

How are you tracking your family’s vaccination records? Download a digital tool here